Anatara Lifesciences Limited Stock Market Press Releases and Company Profile
Pitt Street Research Interviews CEO Steven Lydeamore
Pitt Street Research Interviews CEO Steven Lydeamore

Brisbane, April 16, 2019 AEST (ABN Newswire) - While in Sydney earlier this month, Anatara Lifesciences (googlechartASX:ANR) CEO Steve Lydeamore sat down with Stuart Roberts at Pitt Street Research, one of Australia's most experienced providers of equity research for ASX-listed small and mid cap companies.

Stuart spoke with Steve about the path to market for the Company's new gastrointestinal reprogramming dietary supplement product, called GaRP.

Based on bromelain, GaRP has shown promise as a potential treatment for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Anatara believes there is significant upside for this product given the lack of strong treatment alternatives and the high prevalence of IBS and IBD.

To view the interview, please visit:
http://www.abnnewswire.net/lnk/I42H84NZ

To view the latest Corporate Fact Sheet for further information on Anatara Lifesciences, please visit:
http://abnnewswire.net/lnk/G465OU6A


About Anatara Lifesciences Limited

Anatara Lifesciences ASX ANRAnatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. 

 

https://twitter.com/anataraanr https://www.facebook.com/profile.php?id=61550997392627 https://www.linkedin.com/company/anatara-lifesciences-ltd abnnewswire.com 


Contact

General inquiries
Steven Lydeamore
CEO
Anatara Lifesciences
T: +61-438-027-172
E: slydeamore@anatara.com

Media inquiries:
Jane Lowe
Managing Director
IR Department
T: +61-411-117-774
E: jane.lowe@irdepartment.com.au


ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 3) (Last 30 Days: 32) (Since Published: 4736)